Nucleix Wins €2.5M EU Grant for Lung Cancer Diagnostic

Jul 30, 2018

|

NEW YORK (GenomeWeb) — Israeli molecular diagnostics firm Nucleix announced today that it has won a €2.5 million ($2.9 million) Horizon 2020 grant from the European Commission to continue development of its lung cancer screening test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Nucleix Wins €2.5M EU Grant for Lung Cancer Diagnostic

To read the full story....

Breaking News

Hologic Fiscal Q1 Revenues Rise 89 Percent as Dx Testing Demand Surges

Spectrum Solutions, UCLA Partner to Study Saliva-Based Early-Stage Lung Cancer Detection

T2 Biosystems Preliminary Q4 Revenues Grow 155 Percent, Miss Estimates

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Siemens Healthineers Q1 Diagnostics Revenues Rise 17 Percent on Pandemic-Related Demand

Abbott Panbio SARS-CoV-2 Rapid Antigen Test Nabs CE Mark for Asymptomatic Screening, Self-Collection

Featured White Papers

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

What's Popular?

Abbott Q4 Diagnostics Revenues Up 111 Percent, FY20 Revenues Up 9 Percent

Ambry Genetics Gets FDA Emergency Use Authorization for Coronavirus Test

Infectious Disease Test Firm Talis Biomedical Files for IPO

Fluxergy Aiming to Provide Low-Cost, Multimodal Testing for SARS-CoV-2, Other Disease Targets

NASA Looking to Spin Out Breath Analysis Platform for Use in Diagnostics Applications

Sponsorships